sar
newli
emerg
highli
communic
infecti
diseas
human
first
detect
south
china
novemb
spread
global
much
learn
syndrom
includ
epidemiolog
transmiss
infect
clinic
manifest
diseas
resurg
sar
remain
distinct
possibl
period
therefor
urgent
need
establish
reliabl
anim
model
understand
pathogenesi
infect
develop
vaccin
antivir
drug
prevent
treatment
sar
cynomolgu
macaqu
macaca
fasciculari
ferret
mustela
furo
domest
cat
feli
domesticu
suscept
infect
replic
respiratori
tract
mice
also
recent
demonstr
howev
sequela
infect
respect
progress
histopatholog
chang
degre
immunolog
reaction
durat
viru
replic
anim
model
larg
unknown
given
import
develop
primat
model
elucid
pathophysiolog
mechan
lung
injuri
develop
new
treatment
sar
investig
suscept
rhesu
macaqu
macaca
mulatta
infect
nasal
caviti
inocul
patholog
chang
lung
organ
replic
excret
vivo
immun
respons
specif
macaqu
studi
differ
time
viru
infect
paper
report
find
molecular
detect
replic
vivo
time
seroconvers
develop
neutral
antibodi
respons
dynam
patholog
chang
lung
infect
anim
period
macaqu
age
year
obtain
institut
medic
biolog
kunm
china
cam
pumc
number
inocul
sar
viru
monkey
examin
accord
nation
microbiolog
parasit
spf
specif
standard
verifi
free
antibodi
experi
perform
level
laboratori
exclus
assign
scv
research
institut
laboratori
anim
scienc
cam
anim
studi
protocol
approv
institut
anim
welfar
committe
macaqu
sacrif
accord
studi
design
describ
tabl
design
result
preliminari
experi
four
rhesu
monkey
sacrif
fourth
eighth
day
experi
show
lung
lesion
much
wors
two
monkey
ie
day
inocul
inflammatori
respons
still
persist
day
basi
data
autopsi
find
human
sar
patient
monkey
prepar
experi
examin
fifth
tenth
day
studi
design
focus
behaviour
acut
inflammatori
respons
viru
infect
addit
possibl
complic
emphysema
prolifer
fibrou
tissu
lung
fibrosi
pleural
adhes
later
stage
day
infect
examin
strain
isol
sar
patient
china
cultur
cell
genebank
access
passag
viru
use
tissu
cultur
infecti
dose
per
ml
titr
cell
viru
resequenc
initi
isol
dna
sequenc
preliminari
experi
monkey
infect
tcid
tcid
identifi
optimum
dose
inocul
volum
ml
dilut
per
ml
stock
monkey
drip
nasal
caviti
two
millilitr
wv
lung
tissu
lysat
clinic
diagnos
sar
patient
infect
strain
inocul
monkey
intraven
via
nasal
caviti
anim
subject
daili
measur
anal
temperatur
routin
blood
assay
chest
radiographi
pharyng
swab
sampl
collect
infect
monkey
first
day
inocul
test
nest
rna
isol
trizol
invitrogen
perform
reaction
volum
mm
outer
primer
pair
inner
primer
pair
amplif
paramet
use
sequenti
follow
outer
primer
pair
min
revers
transcript
min
cycl
follow
final
extens
min
inner
primer
pair
min
min
min
cycl
follow
final
extens
min
pcr
product
verifi
nucleotid
sequenc
day
pharyng
swab
sampl
infect
macaqu
inocul
onto
cell
cultur
dmem
gibco
usa
viru
isol
least
three
four
passag
isol
carri
cell
cytopath
effect
cpe
immunofluoresc
assay
ifa
incub
dilut
sar
patient
serum
use
determin
infect
statu
anim
infect
day
viru
inocul
blood
sampl
collect
anim
antibodi
assay
elisa
elisa
kit
huada
beij
china
plate
coat
cell
lysat
cell
sampl
run
duplic
simultan
incub
h
wash
six
time
plate
block
min
wash
five
time
horseradish
peroxidas
hrp
mous
igg
santa
cruz
biotechnolog
santa
cruz
ca
usa
ad
well
incub
h
wash
six
time
develop
solut
mannheim
germani
stop
sulphur
acid
plate
read
spectrophotometr
nm
micropl
reader
labsystem
iem
helsinki
finland
sampl
od
consid
neg
point
determin
use
serum
normal
rhesu
monkey
produc
colour
develop
immunofluoresc
vero
cell
neg
control
determin
neutral
activ
macaqu
serum
serial
dilut
incub
tcid
h
inocul
onto
cell
dilut
serum
test
three
well
cell
cultur
week
observ
cpe
serum
dilut
cell
protect
infect
calcul
autopsi
perform
biosafeti
level
anim
laboratori
differ
interv
infect
organ
grossli
examin
tissu
block
taken
lung
hilar
lymph
node
heart
liver
kidney
intestin
adren
thymu
mesenteri
lymph
node
brain
haematoxylin
eosin
h
e
stain
verhoeff
stain
period
pa
stain
mallori
connect
tissu
mct
stain
phosphotungst
acid
haematoxylin
ptha
gomori
stain
use
identifi
chang
collagen
fibr
elast
reticulin
fibr
alveolar
line
cell
hyalin
membran
mucu
alveolar
space
section
also
stain
monoclon
antibodi
mab
cytokeratin
identifi
origin
differ
type
macrophag
alveoli
septa
differ
time
viru
inocul
mab
use
subset
identif
antigen
detect
variou
tissu
immunohistochem
stain
duplic
section
tissu
sampl
stain
use
complex
peroxidas
techniqu
section
pretreat
proteas
k
sigma
st
loui
mo
usa
min
block
hydrogen
peroxid
goat
serum
min
incub
mab
overnight
antibodi
gift
dr
yiyou
chen
starvax
inc
beij
china
compris
pool
spike
nucleocapsid
mab
slide
develop
use
goat
antibodi
accord
manufactur
recommend
beij
zhongshan
biotech
china
sampl
lung
spleen
lymph
node
fix
formaldehyd
glutaraldehyd
osmium
tetroxid
tissu
sampl
embed
epoxi
resin
thin
section
doubli
stain
uranyl
acet
lead
citrat
examin
tecnai
fei
transmiss
electron
microscop
two
three
day
inocul
eight
monkey
show
temporari
rise
temperatur
peak
initi
subsequ
subsid
remark
chang
leukocyt
count
clinic
sign
symptom
includ
cough
upper
respiratori
tract
catarrh
dyspnoea
loss
appetit
vomit
rash
diarrhoea
absent
moreov
chest
radiographi
neg
experiment
monkey
earli
stage
viru
inocul
sar
coronaviru
rna
detect
bp
fragment
nest
pharyng
swab
nasal
swab
sampl
infect
macaqu
first
day
infect
posit
result
found
eight
monkey
tabl
fifth
day
pharyng
specimen
cultur
vero
cell
show
cpe
suggest
replic
electron
microscopi
vero
cell
cpe
demonstr
typic
particl
cell
cultur
supernat
use
neg
stain
could
also
confirm
electron
microscopi
necropsi
sampl
monkey
tabl
proof
came
immunohistochem
detect
necropsi
sampl
monkey
day
figur
serum
sampl
obtain
eight
anim
prior
inocul
neg
antibodi
antibodi
detect
five
eight
infect
monkey
day
shown
tabl
neutral
assay
demonstr
test
monkey
abl
produc
neutral
antibodi
titr
neutral
antibodi
monkey
follow
day
day
day
show
titr
day
haemorrhag
interstiti
pneumonia
figur
b
interstiti
pneumonia
figur
observ
septa
becam
widen
infiltr
lymphocyt
macrophag
foam
cell
macrophag
engulf
ghost
cell
mostli
degener
red
blood
cell
cytoplasm
figur
alveolar
sac
dilat
fine
bronchiol
fill
cluster
macrophag
haemorrhag
interstiti
pneumonia
figur
accompani
dilat
respiratori
duct
figur
c
lung
oedema
figur
nodular
area
differ
lobe
alveolar
caviti
pack
mainli
macrophag
lymphocyt
figur
b
phagocytosi
erythrocyt
common
figur
prolifer
epitheli
cell
mucu
remark
small
bronchiol
ulcer
granul
tissu
format
prolifer
line
epitheli
cell
small
bronchiol
figur
infiltr
inflammatori
cell
mainli
macrophag
lymphocyt
figur
b
oedema
lung
lesion
interstiti
pneumonia
distinct
figur
gomori
silver
stain
show
destruct
fragment
reticulin
fibr
alveolar
wall
figur
b
monkey
interstiti
pneumonia
haemorrhag
natur
figur
infiltr
macrophag
lymphocyt
septa
figur
b
c
b
c
necrot
foci
liver
left
heart
similar
lesion
report
human
autopsi
find
fibrin
deposit
obviou
alveolar
caviti
form
part
hyalin
membran
alveoli
figur
c
monkey
also
remark
interstiti
pneumonia
pneumon
lung
figur
haemorrhag
area
similar
seen
case
figur
b
c
accumul
macrophag
foam
cell
alveoli
figur
interstiti
pneumonia
still
detect
monkey
day
lesion
scatter
distribut
infiltr
mononuclear
inflammatori
cell
figur
b
evid
chronic
pleuriti
emphysema
figur
b
infiltr
cell
figur
spleen
congest
prolifer
red
pulp
data
shown
focal
necrosi
seen
liver
figur
regen
epitheli
cell
alveoli
figur
b
addit
cell
figur
b
seen
adher
clump
regen
epitheli
cell
small
bronchiol
foci
interstiti
pneumonia
still
found
certain
area
lung
monkey
mild
figur
figur
alveoli
markedli
distend
accompani
local
emphysema
figur
septa
well
preserv
evid
infiltr
lymphocyt
macrophag
septa
figur
monkey
figur
summari
lesion
acut
interstiti
pneumon
observ
monkey
throughout
studi
mark
infiltr
lymphocyt
macrophag
nodular
area
lung
particularli
earli
stage
ie
day
infect
figur
b
figur
b
respiratori
duct
pack
mucu
cell
debri
addit
regener
line
epithelium
seen
simultan
certain
termin
bronchiol
figur
b
desquam
alveolar
line
cell
lung
oedema
hyalin
membran
alveoli
identifi
infect
anim
figur
b
b
howev
lung
lesion
less
intens
compar
patholog
featur
seen
lung
patient
die
sar
sever
lung
infect
becam
mild
anim
sacrif
day
infect
figur
anim
still
infiltr
macrophag
lymphocyt
septa
figur
b
fragment
reticulin
elast
fibr
alveolar
wall
common
figur
b
also
evid
fibrou
tissu
prolifer
develop
emphysema
figur
import
establish
anim
model
order
explor
pathogenesi
sar
test
new
antivir
therapi
vaccin
sar
studi
detect
sequenti
patholog
chang
lung
macaqu
day
pulmonari
lesion
compar
though
less
intens
sar
patient
foci
interstiti
pneumonia
diffus
alveolar
damag
observ
whole
cours
experi
repeat
haemorrhag
oedema
fluid
inevit
result
fibrosi
pulmonari
tissu
patholog
chang
reflect
chang
seen
earli
stage
clinic
sar
case
import
observ
studi
death
infect
anim
sar
infect
rhesu
macaqu
milder
differ
clinic
sign
symptom
patholog
chang
experiment
infect
rhesu
macaqu
compar
human
case
sar
might
due
part
presenc
secondari
infect
human
case
wherea
monkey
use
studi
young
healthi
secondli
treatment
given
sar
patient
might
impact
histolog
chang
thirdli
might
differ
cytopath
effect
human
rhesu
macaqu
igg
antibodi
could
detect
sera
macaqu
day
onward
titr
increas
gradual
neutral
antibodi
protect
assay
show
infect
anim
produc
neutral
antibodi
could
prevent
data
shown
result
also
demonstr
potent
immunogen
suggest
possibl
use
viru
produc
inactiv
attenu
vaccin
recent
report
conclud
macaqu
model
limit
util
studi
sar
pathogenesi
evalu
therapi
particular
lung
lesion
rhesu
cynomolgu
macaqu
infrequ
limit
focal
interstiti
alveolar
inflamm
oedema
lesion
reflect
sever
damag
alveolar
bronchial
cell
damag
observ
result
differ
row
et
al
show
limit
diseas
fouchier
et
al
kuiken
et
al
show
cynomolgu
macaqu
sever
pulmonari
syndrom
resembl
sar
sever
way
reason
differ
clear
note
rhesu
macaqu
chines
origin
use
studi
viral
rna
could
detect
infect
monkey
longest
durat
last
day
addit
viru
could
isol
five
eight
infect
monkey
neutral
antibodi
respons
persist
anim
sacrif
day
thu
base
result
viru
detect
immunolog
respons
patholog
chang
lung
infect
anim
conclud
rhesu
macaqu
model
sar
valuabl
furthermor
studi
simultan
examin
patholog
chang
cytokin
chemokin
profil
lung
anim
might
provid
insight
mechan
lung
injuri
greatli
facilit
screen
evalu
drug
vaccin
